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1. Introduction
Ankaferd hemostat  (ABS; Ankaferd blood stopper, 
İstanbul, Turkey) is a folkloric medicinal plant extract. ABS 
has been conventionally used in Anatolia as a hemostatic 
agent for centuries (1). ABS contains a standardized 
combination of the plants Glycyrrhiza glabra, Thymus 
vulgaris, Alpinia ofﬁcinarum, Vitis vinifera, and Urtica 
dioica. All of these plants have effects on the endothelium, 
the cellular components of blood, the development of new 
blood vessels, cell proliferation, and cell mediators (2,3). 
The hemostatic effect of ABS depends upon the quick 
promotion of a protein network, particularly fibrinogen 
gamma, in relation to the erythrocyte aggregation (1).
In addition to hemostatic functions, antiinflammatory 
(4), antiinfective (5), antifungal (6), and antioxidative 
(4) effects have been demonstrated for ABS. Thymus 
vulgaris has bacteriostatic activity for gram-positive and 
gram-negative bacteria (7–10). Likewise,  Glycyrrhiza 
glabra,  Vitis vinifera,  and  Alpinia officinarum  have been 
shown to be antibacterial agents (11,12). Urtica dioica also 
has significant antibacterial activity against Streptococcus 
pyogenes,  Staphylococcus aureus,  and  Staphylococcus 
epidermidis (12).
ABS is currently licensed for numerous bleeding 
lesions of GIS pathologies, such as peptic ulcers (13), 
fundal varices (14), dieulafoy lesions (15,16), radiation 
colitis (17), rectal ulcers (18) and nonvariceal upper 
gastrointestinal bleeding (19). Most of the bleeding 
lesions were controlled with ABS in all patient groups 
(20–23). Furthermore, ABS is a potent hemostatic drug 
for controlling malignant gastrointestinal (GI) tumors. It 
has successful antineoplastic effects on colon cancer (as 
represented by the in vitro effects on CaCo-2 cells) (24). 
It significantly decreases tumor microvessel density (25). 
Almost 70% of gastric ulcer and 85% to 95% of duodenal 
ulcer patients have coexisting H. pylori  infections 
(26,27).   It is well recognized that  H. pylori  eradication 
therapy can reduce the repetition of peptic ulcer. Several 
different studies support the important role played by H. 
pylori  in mucosa-associated lymphoid tissue (MALT) 
lymphomagenesis. Chronic infection with  H. pylori  is 
significantly related with the induction of gastric lymphoid 
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follicles, representing the proposed first step in MALT 
lymphomagenesis of lymphoid enlargement (28). 
This study was carried out to determine the effects of 
ABS on the fate of H. pylori strains. Our study also aimed to 
elucidate alterations in the antimicrobial resistance of three 
different H. pylori strains. We also intended to determine 
alcohol levels in ABS samples in order to elucidate the 
impact of ABS over gastric acidity and possible effects 
on gastric mucosa. Informed consent was obtained from 
blood donors for the procedure for this study.
2. Materials and methods
2.1. Strains
Strain 1 was obtained from a culture collection ATCC 
43504 and passaged three times for viability. Strain 2 was 
isolated from a gastric ulcer patient and Strain 3 was isolated 
from a gastritis patient. Wild strains were identified using 
biochemical scheme summarized in Figure 1 and 16s 
rRNA sequencing was held for wild strains for molecular 
confirmation of biochemical results. 
2.2. Biochemical identification of Helicobacter spp. 
Identification of different Helicobacter spp. was done 
using biochemical tests. (Anonymous. Identification of 
Helicobacter species. UK Standards for Microbiology 
Investigations.  Bacteriology – Identification | ID 26, Issue 
no: 3, Issue date: 03.07.15, Page: 2 of 27)
Strains were streaked on Colobia Agar Base (CM0331, 
Oxoid, England) supplemented with DENT (Vancomycin, 
Trimethoprim, Cefsulodin, Amphotericin B) (SR0147, 
Oxoid, England). All strains were incubated at 37 °C under 
microaerophilic conditions (CampyGen, CN025, Oxoid, 
England) for 5–10 days.
2.3. Response of H. pylori strains to ABS 
All strains were collected in a tube using a sterile swab 
and washed using sterile saline (0.85%) three times. Each 
strain was mixed to form a final cocktail of H. pylori and 
were grouped to determine response to 0.5%, 1%, 1.5%, 
2%, 2.5%, and 3% of ABS at 5, 60, 90, 120 s and 3, 5, 10, 15, 
30, and, 60 min. This study was repeated three times. 
2.4. Changes in antibiotic susceptibility of H. pylori 
strains after ABS applications
One percent ABS was added to all strains and 
antimicrobial susceptibility was held at 30 and 60 
min of application. Clarithromycin (CT 1623, Oxoid, 
England), Metronidazole (CT 0067, Oxoid, England), 
Tetracycline (CT 0054, Oxoid, England), and Amoxicillin 
(CT0161, Oxoid, England) discs were used to determine 
susceptibility changes. The following reference strains are 
used: Staphylococcus aureus  ATCC® 25923, Escherichia 
coli  ATCC® 25922, Pseudomonas aeruginosa  ATCC® 
27853, Haemophilus influenza  ATCC® 49247, Neisseria 
gonorrhoeae  ATCC® 49226, Streptococcus pneumoniae 
ATCC® 49619, Escherichia coli ATCC® 35218 and H. pylori 
ATCC 43504. Results were evaluated using the EUCAST 
2016 breaking points. Informed consent was not taken for 
the reason that people are not included at this step.
3. Results
The results indicating the effects of ABS on the studied 
bacteria are depicted in  Table 1. The relative efficacy of 
ABS solutions to achieve significant logarithmic reduction 
in foodborne pathogens  H. pylori. The distribution of 
antibiotic susceptibility application for determined periods 
is depicted in Figure 2.
The alcohol ingredient studies revealed a small ethanol 
peak which was thought to be found by fermentation of 
grape seeds. Additionally, ethyl acetate was found in the 
ABS. The amounts of these ingredients were less those 
found in kefir. The alcohol ingredient studies are depicted 
in Figure 3 and Table 2. Technical appendix, statistical 
code, and dataset available from the corresponding author 
at rafiyesarigul@gmail.com
4. Discussion
In this study, the efficacy of ABS was demonstrated in the 
antibiotic resistant H. pylori strain for the first time. There 
are no published studies in the literature investigating 
whether ABS was effective on antibiotic-resistant H. pylori 
strain. With this study, we can hypothesize that ABS in the 
stomach increases oxygenation and forms the basis for H. 
pylori eradication.
Our findings, in this study, further supported 
previous research findings that ABS has antibacterial 
effect (5, 29). Each of herbaceous plants in ABS has 
known effects on blood cells, endothelium, angiogenesis, 
cell proliferation, and other physiological mediators 
(1).  Thymus vulgaris  has antioxidative properties and 
antimicrobial activity (3). Recent reports have shown 
that  Glycyrrhiza glabra  has antimicrobial, antioxidant, 
antifungal as well as antiinflammatory effects (30). Alpinia 
officinarum has antioxidant and antimicrobial activity. 
(31). Vitis vinifera  seed extract is related with a 
large spectrum of pharmacological effects including 
antioxidative, antiinflammatory and antimicrobial effects 
(32).   Likewise,  Urtica dioica  has been reported as an 
antimicrobial agent in pharmaceutical and food industry 
(33). Anti-H. pylori effect of ABS could be related with the 
protein library of the drug. Functional proteomic analyses 
were  previously performed by Demiralp et al. regarding 
proteomics of ABS and its effect (34).
The antimicrobial activity of ABS has been demonstrated 
against many microorganisms (29). Some studies have 
shown that ABS is highly effective against several gram-
negative and gram-positive bacteria including frequent 
foodborne microorganisms (35). ABS suppresses the 
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Figure 1. Biochemical identification of Helicobacter spp. 
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Figure 1. Biochemical identification of Helicobacter spp. 
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development of several common origins of nosocomial 
infections, including methicillin-resistant  Staphylococcus 
aureus, vancomycin-resistant enterococci, and imipenem-
resistant Acinetobacter isolates (5). Several recent reports 
demonstrated  in vitro  antibacterial activity of ABS 
against other multiantibiotic-resistant bacteria, such as E. 
coli,  Enterococcus spp.,  Pseudomonas spp., and  Klebsiella 
spp., also fungi including  Aspergillus spp.,  Candida 
0
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Figure 2. The changes in antibiotic susceptibility after ABS application for determined periods. 
Figure 3. Peak table-channel.
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albicans, and  Mucor spp.  (36). Koluman et  al. showed 
that ABS inhibits the in vivo growth of gram-positive and 
gram-negative bacteria (37). Exposure to ABS may support 
enhanced oxygenation through erythrocyte aggregation 
(29,36,38). This study also showed that Ankaferd has 
anti-H. pylori effects.
Wound healing, hemostasis, and infection are 
pathobiologically connected to each other (39). 
Antithrombin and prohemostatic activities of ABS are 
related to fibrinogen gamma chain and prothrombin 
by functional proteomic analyses. (40).  Gastric ulcers 
are in general caused by H. pylori and the chronic use 
of antiinflammatory medications. The antioxidant 
components of ABS modulate the cellular proliferation and 
vascular dynamics as well as the hemostatic hemodynamic 
activity (41). ABS might be beneficial by protecting the 
gastric mucosa from oxidative injury or by accelerating 
the healing of gastric ulcers (42). Another study showed 
that ABS was associated with significantly healed gastric 
mucosal structure. This might be due to the antioxidant 
and gastroprotective effects of ABS (43). ABS can improve 
the wound-healing process by providing inhibition of 
extra cellular matrix-degrading enzymes during wound 
repair. ABS enhanced the stimulated migration of 3T3 
fibroblasts to an artificial wounded area. The antibiofilm 
activity of ABS against oral streptococci was revealed 
with in vitro analysis by Boran et al. (44). Therefore, oral 
administration of ABS could not only treat GI hemorrhage 
but also ongoing infections and wound-related pathologies 
as well (43–45).
Herbal medicines could increase the abundance of 
many bacteria known to support human health status, 
involving Bifidobacterium spp., Lactobacillus spp., and 
Bacteroides spp. (46). Peterson et al. suggested that 
herbal medicine may induce blooms of butyrate- and 
propionate-producing species. Ulmus rubra significantly 
increased the relative abundance of butyrate-producing 
bacteria, whereas Glycyrrhiza glabra induced the largest 
increase in propionate-producing species (46). Glycyrrhiza 
glabra is an essential component of ABS (38). Zhou et 
al. indicated that Vitis vinifera have potential prebiotic 
effects on modulating the gut microbiota composition and 
generating SCFAs that contribute to the improvements 
of host health (47). Mandalari et al. also showed that the 
supplementation with Vitis vinifera tended to promote the 
proliferation of Bifidobacterium spp. (48). Vitis vinifera 
is also present in the standardized extract of ABS (38). 
Bifidobacterium bifidum BF-1 suppresses H. pylori-induced 
genes in human epithelial cells. The preincubation with BF 
1 strain, a probiotic strain H. pylori-associated gastritis, 
suppresses induction of IL-8 by the pathogen (49). Thus, 
ABS might contribute to the treatment of H. pylori both 
directly and indirectly via improving biological microbiota 
such as increasing Bifidobacterium spp. of ABS. Future 
experimental in vivo and/or clinical studies are needed 
to demonstrate whether ABS had any influence on the 
growth of the microbioata including Bifidobacteria.
There are pathobiological associations among H. 
pylori and lymphoma development (28). Preliminary 
evidence that ABS has antilymphoma effects in vitro (50) 
and current findings that ABS has anti-H. pylori effects. 
Oral ABS administration may alter H. pylori growth for 
the prevention of neoplastic lymphoid mucosal tissue 
proliferation; a hypothesis that should be tested in future 
experimental approaches. The involvement of H. pylori in 
MALT lymphoma is well established and based on the 
epidemiological, pathological, clinical, and bacteriological 
evidence (28). Akalın et al. proposed that ABS can cause 
apoptosis in the lymphoid neoplastic cells since there was a 
high content of human IL-4 in ABS solution. They showed 
that ABS-treated B-chronic lymphocytic cells (B-CLL) (at 
doses of 0.5, 1, and 2 µg/mL) ceased to inflate and more 
than 50% of tumor cells died compared to 0.1 and 0.25 
µg/mL doses. Moreover, the transformation of B-CLL cells 
to the blastic aggressive lymphoid forms was prevented 
by the addition of ABS to the culture medium (50). As 
presented in our current study, the anti-H. pylori effect of 
ABS may be linked to the previously demonstrated anti-
lymphoma effects of the drug. ABS shall be considered as 
beneficial in the associated lymphoid malignancies. Future 
experimental in vivo and/or clinical studies are needed 
to shed further light on the interrelationship between 
neoplastic GI  lymphoid mucosal tissue and antineoplastic 
within the context of antiproliferative actions. In this study, 
we showed the efficacy of ABS solutions, including the 
logarithmic reduction H. pylori and foodborne pathogens.
Table 2. The alcohol ingredient study.
                                                         Peak table-channel
Peak Time Area Height Concentration Units Name
1 4.833 239 92 0.000 g/hL ethyl acetate
2 6.44 21041 5504 0.000 g/hL ethanol
Total 21280 5596
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There is a growing body of argument for the 
accomplished use of ABS in different states of GI bleeding. 
In an observational study of “intention-to-treat” analysis 
by Ozaslan et al. (51), ﬁve patients with bleeding peptic 
ulcers were treated with ABS as the primary hemostatic 
agent.  Similarly in a case report by Purnak et al., a 
successful control of bleeding was reported in a peptic ulcer 
patient (13). ABS was selected due to the impotence and 
difﬁculties of the traditional antihemorrhagic protection 
agents (19). Endoscopic topical administration of ABS for 
neoplastic gastrointestinal bleeding was also effectively 
shown in many studies (52,53).  The case series by Kurt et 
al. showed that local administration of ABS to patients with 
neoplastic upper GI bleeding provided hemorrhage control 
and no complications were seen following the procedure 
(53). Thanks to the  mechanical hemostasis obtained by 
ABS, Turhan et al. (25) reported that ABS reduces tumor 
vascularization in gastrointestinal carcinoma bleeds. In 
another report, local ABS administration was applied 
in two patients with GI bleeds as a result of rectal and 
gastric neoplasm. Local ABS administration to the lesion 
was shown to control the bleeding completely. Based on 
these results, the authors suggested that a secondary 
and more permanent mechanism of hemostasis over the 
initial protein network might have been started by ABS. 
In addition, there is no alcohol in ABS. Therefore, there is 
no risk of any gastric mucosal damage due to this reason.
In conclusion, the most striking result of our 
investigation is the documentation of a remarkable 
antimicrobial activity of ABS against three different strains 
of H. pylori. The pleiotropic effects of ABS on the blood cells, 
vascular endothelium angiogenesis, cellular proliferation, 
vascular dynamics, and cellular mediators should be 
researched to determine its capacity role in wound-healing 
(2), and pathological states, such as infectious diseases and 
inflammation. ABS is an original hemostatic factor within 
many junction of hemostasis, neoplasia, and infection. 
Our findings cast future experimental and clinical ABS 
research to be placed in the clinical management of H. 
pylori-induced GI lesions.
References
1. Beyazit Y, Kurt M, Kekilli M, Goker H, Haznedaroglu IC. 
Evaluation of hemostatic effects of Ankaferd as an alternative 
medicine. Altern Med Rev 2010; 15: 329-336.
2. Goker H, Haznedaroglu I, Ercetin S, Kirazli S, Akman U, 
Ozturk Y, Firat HC. Haemostatic actions of the folkloric 
medicinal plant extract Ankaferd Blood Stopper®. Journal of 
International Medical Research 2008; 36: 163-170.
3. Lee S-J, Umano K, Shibamoto T, Lee K-G. Identification of 
volatile components in basil (Ocimum basilicum L.) and thyme 
leaves (Thymus vulgaris L.) and their antioxidant properties. 
Food Chemistry. 2005;91:131-7.
4. Koçak E, Akbal E, Taş A, Köklü S, Karaca G, Can M, Kosem 
B, Ustun H. Anti-inflammatory efficiency of Ankaferd 
blood stopper in experimental distal colitis model. Saudi 
Journal of Gastroenterology: Official Journal of the Saudi 
Gastroenterology Association. 2013;19:126.
5. Saribas Z, Sener B, Haznedaroglu I, Hascelik G, Kirazli S, 
Goker H. Antimicrobial activity of Ankaferd Blood Stopper® 
against nosocomial bacterial pathogens. Open Medicine 2010; 
5: 198-202.
6. Ciftci S, Keskin F, Ozcan SK, Erdem MA, Cankaya B, Bingol 
R, Kasapoglu C. In vitro antifungal activity of Ankaferd 
Blood Stopper against Candida albicans. Current Therapeutic 
Research 2011; 72: 120-126.
7. Agnihotri S, Vaidya A. A novel approach to study antibacterial 
properties of volatile components of selected Indian medicinal 
herbs. Indian Journal of Experimental Biology. 1996; 34: 712-
715.
8. Abu-Ghazaleh BM. Inhibition of Aeromonas caviae and 
A. sobria by sodium choloride, citric acid, ascorbic acid, 
potassium sorbate and extracts of Thymus vulgaris. Japanese 
Journal of Infectious Diseases 2000; 53: 111-115.
9. Essawi T, Srour M. Screening of some Palestinian medicinal 
plants for antibacterial activity. Journal of Ethnopharmacology 
2000; 70: 343-349.
10. Marino M, Bersani C, Comi G. Antimicrobial activity of 
the essential oils of Thymus vulgaris L. measured using a 
bioimpedometric method. Journal of Food Protection 1999; 
62: 1017-1023.
11. Fukai T, Marumo A, Kaitou K, Kanda T, Terada S, Nomura T. 
Antimicrobial activity of licorice flavonoids against methicillin-
resistant Staphylococcus aureus. Fitoterapia 2002; 73: 536-539.
12. Janssen A, Scheffer J. Acetoxychavicol acetate, an antifungal 
component of Alpinia galanga1. Planta medica 1985; 51: 507-
511.
13. Purnak T, Ozaslan E, Beyazit Y, Haznedaroglu IC. Upper 
gastrointestinal bleeding in a patient with defective hemostasis 
successfully treated with ankaferd blood stopper. Phytotherapy 
research 2011; 25: 312-313.
14. Tuncer I, Doganay L, Ozturk O. Instant control of fundal 
variceal bleeding with a folkloric medicinal plant extract: 
Ankaferd Blood Stopper. Gastrointestinal Endoscopy 
2010;71:873-5.
15. Kurt M, Kacar S, Onal I, Akdogan M, Haznedaroglu I. 
Ankaferd Blood Stopper as an effective adjunctive hemostatic 
agent for the management of life-threatening arterial bleeding 
of the digestive tract. Endoscopy 2008; 40: E262.
354
ÇİFTÇİLER et al. / Turk J Med Sci
16. Kurt M, Onal IK, Akdogan M, Kekilli M, Arhan M, Sayilir 
A, Oztas E, Haznedaroglu IC. Ankaferd Blood Stopper for 
controlling gastrointestinal bleeding due to distinct benign 
lesions refractory to conventional antihemorrhagic measures. 
Canadian Journal of Gastroenterology and Hepatology 2010; 
24: 380-384.
17. Ozaslan E, Purnak T, Yildiz A, Akar T, Avcioglu U, Haznedaroglu 
I. The effect of Ankaferd blood stopper on severe radiation 
colitis. Endoscopy 2009; 41: E321-E2.
18. Ibis M, Kurt M, Onal IK, Haznedaroglu IC. Successful 
management of bleeding due to solitary rectal ulcer via 
topical application of Ankaferd blood stopper. The Journal of 
Alternative and Complementary Medicine 2008; 14: 1073-1074.
19. Ozaslan E, Purnak T, Yildiz A, Haznedaroglu IC. The effect 
of a new hemostatic agent for difficult cases of non-variceal 
gastrointestinal bleeding: Ankaferd blood stopper. Hepato-
gastroenterology 2010; 57: 191-194.
20. Matsuda H, Ando S, Kato T, Morikawa T, Yoshikawa M. Inhibitors 
from the rhizomes of Alpinia officinarum on production of 
nitric oxide in lipopolysaccharide-activated macrophages and 
the structural requirements of diarylheptanoids for the activity. 
Bioorganic and Medicinal Chemistry 2006; 14: 138-142.
21. Testai L, Chericoni S, Calderone V, Nencioni G, Nieri P, 
Morelli I, Martinotti E. Cardiovascular effects of Urtica 
dioica L.(Urticaceae) roots extracts: in vitro and in vivo 
pharmacological studies. Journal of Ethnopharmacology 2002; 
81: 105-109.
22. Sheela M, Ramakrishna M, Salimath BP. Angiogenic and 
proliferative effects of the cytokine VEGF in Ehrlich ascites 
tumor cells is inhibited by Glycyrrhiza glabra. International 
immunopharmacology 2006; 6: 494-498.
23. Barka EA, Belarbi A, Hachet C, Nowak J, Audran JC. 
Enhancement of in vitro growth and resistance to gray mould 
of Vitis vinifera co‐cultured with plant growth‐promoting 
rhizobacteria. FEMS Microbiology Letters 2000; 186: 91-95.
24. Goker H, Kilic E, Cetinkaya D, Buyukasik Y, Aksu S, Turgut 
M, Haznedaroglu IC. Anti-cancer Activity of Ankaferd on 
Human Colon Cancer (CACO-2) in vitro. In: Haznedaroğlu IC 
GH, Özdemir O, Koşar A, Fırat H, editors. Ankaferd: Scientific 
Perspectives and Basic Clinical Data. Istanbul, Turkey: Naviga 
Publications, 2008, p. 108.
25. Turhan N, Kurt M, Shorbagi A, Akdogan M, Haznedaroglu IC. 
Topical Ankaferd Blood Stopper administration to bleeding 
gastrointestinal carcinomas decreases tumor vascularization. 
The American Journal of Gastroenterology. 2009; 104: 2874.
26. Yamada T, Searle JG, Ahnen D, Aipers DH, Greenberg HB, 
Gray M, Joscelyn  KB, McNair, Jeffrey PC, Kuffman G et al. 
Helicobacter pylori in peptic ulcer disease. Jama. 1994; 272: 65-
69.
27. Chen TS, Luo JC, Chang FY. Prevalence of Helicobacter pylori 
infection in duodenal ulcer and gastro‐duodenal ulcer diseases 
in Taiwan. Journal of Gastroenterology and Hepatology. 
2010;25:919-22.
28. Floch P, Mégraud F, Lehours P. Helicobacter pylori strains and 
gastric MALT lymphoma. Toxins 2017; 9: 132.
29. Fisgin NT, Cayci YT, Coban AY, Ozatli D, Tanyel E, Durupinar 
B, Tulek N. Antimicrobial activity of plant extract Ankaferd 
Blood Stopper®. Fitoterapia 2009; 80: 48-50.
30. Dirican E, Turkez H. In vitro studies on protective effect of 
Glycyrrhiza glabra root extracts against cadmium-induced 
genetic and oxidative damage in human lymphocytes. 
Cytotechnology 2014; 66: 9-16.
31. Srividya A, Dhanabal S, Misra V, Suja G. Antioxidant and 
antimicrobial activity of Alpinia officinarum. Indian Journal of 
Pharmaceutical Sciences. 2010; 72: 145.
32. Nassiri‐Asl M, Hosseinzadeh H. Review of the pharmacological 
effects of Vitis vinifera (grape) and its bioactive constituents: 
an update. Phytotherapy Research 2016; 30: 1392-403.
33. Modarresi-Chahardehi A, Ibrahim D, Fariza-Sulaiman S, 
Mousavi L. Screening antimicrobial activity of various extracts 
of Urtica dioica. Revista de Biologia Tropical 2012; 60: 1567-
1576.
34. Demiralp DÖ, Haznedaroğlu İC, Akar N. Functional 
proteomic analysis of Ankaferd Blood Stopper. Turkish Journal 
of Hematology 2010; 27: 2.
35. Akkoc N, Akceik M, Haznedaroglu I, Goker H, Aksu S, Kirazli 
S, Firat H. In vitro anti-bacterial activities of Ankaferd blood 
stopper. International Journal of Laboratory Hematology 2008; 
30: 95.
36. Akkoc N, Akcelik M, Haznedaroglu IC, Goker H, Turgut M, 
Aksu S, Firat H. In vitro anti-bacterial activities of Ankaferd 
medicinal plant extract. Turkiye Klinikleri Tip Bilimleri 
Dergisi 2009; 29: 410-415.
37. Koluman A, Akar N, Haznedaroğlu İC. Antibacterial Activities 
of Ankaferd Hemostat (ABS) on Shiga Toxin-Producing 
Escherichia coli and Other Pathogens Significant in Foodborne 
Diseases. Turkish Journal of Hematology 2017; 34: 93.
38. Haznedaroglu BZ, Beyazit Y, Walker SL, Haznedaroglu IC. 
Pleiotropic cellular, hemostatic, and biological actions of 
Ankaferd hemostat. Critical Reviews in Oncology/Hematology 
2012; 83: 21-34.
39. Aktaş A, Er N, Korkusuz P, Zeybek D, Onur MA, Tan G, 
Ozdemir O, Karaismailoglu E, Karabulut E. Ankaferd-induced 
early soft tissue wound healing in an experimental rat model. 
Turkiye Klinikleri J Med Sci 2013; 33: 1344-1353.
40. Ozel-Demiralp D, İğci N, Ayhan B, Eğin Y, Haznedaroglu 
IC, Akar N. Prohemostatic and antithrombin activities of 
Ankaferd hemostat are linked to fibrinogen gamma chain and 
prothrombin by functional proteomic analyses. Clinical and 
Applied Thrombosis/Hemostasis 2012; 18: 604-610.
41. Huri E, Haznedaroglu IC, Akgul T, Astarci M, Ustun H, 
Germiyanoulu C. Biphasic effects of ankaferd blood stopper on 
renal tubular apoptosis in the rat partial nephrectomy model 
representing distinct levels of hemorrhage. Saudi Medical 
Journal 2010; 31: 864-868.
355
ÇİFTÇİLER et al. / Turk J Med Sci
42. Repetto M, Llesuy S. Antioxidant properties of natural 
compounds used in popular medicine for gastric ulcers. 
Brazilian Journal of Medical and Biological Research 2002; 35: 
523-534.
43. Beyazit Y, Kekilli M, Haznedaroglu IC, Kayacetin E, Basaranoglu 
M. Ankaferd hemostat in the management of gastrointestinal 
hemorrhages. World Journal of Gastroenterology 2011; 17: 
3962.
44. Boran R, Baygar T, Saraç N, Uğur A. Ankaferd Blood Stopper 
with antibiofilm potential successfully inhibits the extracellular 
matrix degradation enzymes and promotes wound healing of 
3T3 fibroblasts in vitro. Turkish Journal of Medical Science 
2018; 48: 627-634.
45. Hacıoğlu SK, Doğu MH, Sarı İ, Keskin A. Successful 
treatment of refractory gastrointestinal bleeding by systemic 
(oral) Ankaferd Blood Stopper in a patient with Glanzmann 
thrombasthenia. Balkan Medical Journal 2015; 32: 218.
46. Peterson CT, Sharma V, Uchitel S, Denniston K, Chopra D, Mills 
PJ, Peterson SN. Prebiotic Potential of Herbal Medicines Used 
in Digestive Health and Disease. The Journal of Alternative and 
Complementary Medicine 2018; 27: 656-665.
47. Zhou L, Wang W, Huang J, Ding Y, Pan Z, Zhao Y, Zhang R, Hu 
B, Zeng X. In vitro extraction and fermentation of polyphenols 
from grape seeds (Vitis vinifera) by human intestinal 
microbiota. Food and Function 2016; 7: 1959-1967.
48. Mandalari G, Chessa S, Bisignano C, Chan L, Carughi A. The 
effect of sun-dried raisins (Vitis vinifera L.) on the in vitro 
composition of the gut microbiota. Food and Function 2016; 
7: 4048-4060.
49. Shirasawa Y, Shibahara-Sone H, Iino T, Ishikawa F. 
Bifidobacterium bifidum BF-1 suppresses Helicobacter pylori-
induced genes in human epithelial cells. Journal of Dairy 
Science 2010; 93: 4526-4534.
50. Akalin I, Fatma V, Haznedaroglu IC, Sayinalp N, Salih A, 
Buyukasik Y, Goker H. Acute in vitro effects of ABS (Ankaferd 
Hemostat) on the lymphoid neoplastic cells (B-CLL and RAJI 
tumor cell lines). International Journal of Hematology and 
Oncology 2014; 27: 253-259.
51. Ozaslan E, Purnak T, Yildiz A, Haznedaroglu IC. A new 
practical alternative for tumoural gastrointestinal bleeding: 
Ankaferd blood stopper. Digestive and Liver Disease 2010; 42: 
594-595.
52. Kurt M, Disibeyaz S, Akdogan M, Sasmaz N, Aksu S, 
Haznedaroglu İC. Endoscopic application of ankaferd blood 
stopper as a novel experimental treatment modality for upper 
gastrointestinal bleeding: a case report. The American Journal 
of Gastroenterology 2008; 103: 2156.
53. Kurt M, Akdogan M, Onal IK, Kekilli M, Arhan M, Shorbagi 
A, Aksu S, Kurt O, Haznedaroglu IC. Endoscopic topical 
application of Ankaferd Blood Stopper for neoplastic 
gastrointestinal bleeding: A retrospective analysis. Digestive 
and Liver Disease 2010; 42: 196-199.
